Video

The ZUMA-3 Trial: Clinical Endpoints

Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.

Video Player is loading.
Current Time 0:00
Duration 7:15
Loaded: 2.26%
Stream Type LIVE
Remaining Time 7:15
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Newsletter

Stay up to date on the most recent and practice-changing oncology data